Latest Ratios: P/E Ratio 9.2x · EV/EBITDA N/A · ROE 5.1%. (2012–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $36M | $82M | $108M | $85M | $51M | $278M | $133M | $25M | $29M | $57M | — |
| Enterprise Value | $22M | $68M | $61M | $14M | $30M | $164M | $70M | $24M | $13M | $32M | — |
| P/E Ratio → | 9.22 | 17.01 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | 185.38 | 13.28 | 2.61 | — | — | — |
| P/B Ratio | 0.29 | 0.53 | 3.09 | 1.41 | 0.93 | 2.58 | 1.98 | 4.42 | 3.14 | 5.16 | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | 109.08 | 7.01 | 2.47 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | 100.0% | 50.9% | 52.9% | — | — | — |
| Operating Margin | — | — | — | — | — | -2761.7% | -34.3% | -35.9% | — | — | — |
| Net Profit Margin | — | — | — | — | — | -2705.8% | -33.7% | -35.6% | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 5.1% | 5.1% | -141.9% | -141.9% | -67.2% | -46.3% | -9.3% | -46.3% | -228.1% | -267.4% | — |
| ROA | 4.5% | 4.5% | -110.8% | -124.4% | -62.0% | -43.1% | -8.6% | -24.8% | -96.1% | -167.4% | -148.1% |
| ROIC | -43.0% | -43.0% | — | -545.5% | -308.3% | — | -59.5% | — | — | — | — |
| ROCE | -37.7% | -37.7% | -147.2% | -151.2% | -69.7% | -46.9% | -9.1% | -35.2% | -172.7% | -140.8% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.01 | 0.00 | 0.01 | 0.00 | 0.01 | 0.18 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.09 | -1.34 | -1.17 | -0.37 | -1.06 | -0.94 | -0.24 | -1.77 | -2.32 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -1522.50 | -1522.50 | — | — | -1007.31 | -989.51 | -88.13 | -151.13 | -1215.74 | -245.98 | -19.79 |
Net cash position: cash ($14M) exceeds total debt ($38000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 35.56 | 35.56 | 3.41 | 5.64 | 17.07 | 11.70 | 37.37 | 3.50 | 2.69 | 4.55 | 0.11 |
| Quick Ratio | 35.56 | 35.56 | 3.41 | 5.64 | 16.62 | 11.70 | 36.83 | 3.09 | 2.69 | 4.55 | 0.11 |
| Cash Ratio | 3.08 | 3.08 | 3.36 | 5.57 | 14.03 | 11.51 | 35.44 | 1.52 | 2.52 | 4.23 | 0.02 |
| Asset Turnover | — | — | — | — | — | 0.01 | 0.14 | 1.11 | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | 5.03 | 7.06 | — | — | 0.83 |
| Days Sales Outstanding | — | — | — | — | — | 289.32 | 73.09 | 77.07 | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 10.8% | 5.9% | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $71M | $38M | $20M | $11M | $9M | $6M | $2M | $1M | $918858 | $939241 |
Imminent capital structure dilution
According to recent market data, the company trades at a P/B ratio of 0.29, which suggests that investors are heavily discounting the firm's book value in anticipation of further asset erosion and the potential for significant future equity dilution to fund ongoing clinical development activities.
The low P/B multiple appears to reflect deep market skepticism regarding the company's ability to convert its intellectual property into a commercially viable asset. Given the absence of meaningful revenue or earnings, traditional valuation metrics like P/E are largely irrelevant, and the current pricing likely represents a distressed valuation of the remaining cash and potential pipeline value.
As reported in financial statements, the company's ROIC has consistently remained in negative territory, with a -3.3% reading in 2026Q1, indicating that the firm is currently destroying shareholder capital rather than compounding it through its ongoing research and development investments in the DKK1 pathway.
The persistent negative return on invested capital highlights the structural challenge of a pre-revenue biotech firm where capital is consumed by high-cost clinical trials without immediate commercial offsets. This trend suggests that until the company achieves a successful clinical readout or partnership milestone, the return profile will likely remain suppressed by the heavy burden of R&D expenditures.
Based on the latest quarterly filings, the current ratio has experienced extreme volatility, dropping from 35.56 in 2025Q4 to 27.28 in 2026Q1, which underscores the company's precarious liquidity position as it burns through its remaining cash reserves to meet essential clinical trial obligations.
While the current ratio remains numerically high, it is misleading in a pre-revenue context where cash is the only truly liquid asset available to fund operations. The rapid decline in cash reserves warrants close monitoring, as the company's ability to sustain its current burn rate without external financing appears increasingly constrained.
Investors frequently misapply the P/E ratio to this business model, as the reported 9.22 TTM P/E is a mathematical artifact of non-operating accounting adjustments rather than a reflection of sustainable earning power or the company's actual operational performance in the biotechnology sector.
Using P/E to evaluate a pre-revenue clinical-stage entity obscures the reality of its cash-burning nature and ignores the fundamental importance of the 'zero-cash date.' Analysts should instead focus on cash runway and the probability-weighted net present value of the clinical pipeline, as these metrics provide a more accurate assessment of the firm's long-term viability.
Includes 30+ ratios · 14 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CYPH stock.
Cypherpunk Technologies Inc.'s current P/E ratio is 9.2x. The historical average is 17.0x.
Cypherpunk Technologies Inc.'s return on equity (ROE) is 5.1%. The historical average is -96.4%.
Based on historical data, Cypherpunk Technologies Inc. is trading at a P/E of 9.2x. Compare with industry peers and growth rates for a complete picture.